Belgian biopharmaceutical company TiGenix has received a licence for the commercial production of expanded adipose-derived stem cells (eASCs) at its extended manufacturing facility in Madrid, Spain.

The company uses the anti-inflammatory properties of allogeneic or donor-derived stem cells to develop new treatments for serious medical conditions.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The commercial production licence was secured by the company after an inspection conducted by the Spanish Medicines Agency (AEMPS).

The licence provides capacity for the potential initial commercial roll out of Cx601 across Europe.

Cx601 is an investigational stem cell therapy used to treat complex perianal fistulas in patients with Crohn’s disease, a chronic inflammatory disease of the intestine.

“We have now significantly increased our manufacturing capacity, a key step in the preparation for commercialisation of Cx601 in Europe and in the further development of our pipeline.”

Additionally, the extended manufacturing facility will offer sufficient capacity for the production of other pipeline products, including Cx611, currently under development by TiGenix.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Currently undergoing a Phase I/II trial, Cx611 is an intravenous administration of allogeneic eASCs for the treatment of severe sepsis, which is a life-threatening complication of infection that results in systemic inflammation and organ failure.

TiGenix chief technical officer Wilfried Dalemans said: “We are very pleased with this approval for our expanded facility, which confirms our state-of-the-art good manufacturing practices (GMP) manufacturing capabilities in the stem cell field.

“We have now significantly increased our manufacturing capacity, a key step in the preparation for commercialisation of Cx601 in Europe and in the further development of our pipeline.”

TiGenix has recently given an exclusive development and commercialisation licence for Cx601 outside of the US to Takeda.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now